ArticleLeukemia2025

Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.

Inga Hund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.